Silence Therapeutics PLC Grant of Employee Options (6452W)

TIDMSLN

RNS Number : 6452W

Silence Therapeutics PLC

27 April 2021

Grant of Employee Options

27(th) April 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it has granted 160,000 options under the Silence Therapeutics plc 2018 Employee Long Term Incentive Plan to Giles Campion, M.D., Executive Director of the Company. The options will have a strike price of GBP5.50, the mid-market closing price on AIM on April 22, 2021.

The notification below is made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Giles Campion, M.D. 
     ---------------------------  ------------------------------------------------ 
 2.   Reason for the notification 
     ----------------------------------------------------------------------------- 
 a)   Position / status            Executive Director 
     ---------------------------  ------------------------------------------------ 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ------------------------------------------------ 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ------------------------------------------------ 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ------------------------------------------------ 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------------- 
 a)   Description of               Ordinary Shares of nominal value 5 pence 
       the financial instrument,    each in the capital of Silence Therapeutics 
       type of instrument           plc 
 
       Identification 
       code 
                                    ISIN for Silence Therapeutics plc Ordinary 
                                    Shares: 
                                    GB00B9GTXM62 
     ---------------------------  ------------------------------------------------ 
 b)   Nature of the transaction    Grant of options under the Silence Therapeutics 
                                    plc 2018 Employee Long Term Incentive 
                                    Plan 
     ---------------------------  ------------------------------------------------ 
 c)   Prices(a) and volume(s)        Price    Volume 
                                      Nil      160,000 
                                              -------- 
     ---------------------------  ------------------------------------------------ 
 d)   Aggregated information 
       - Aggregated volume           N/A 
       - Price 
     ---------------------------  ------------------------------------------------ 
 e)   Date of the transaction      22 April 2021 
     ---------------------------  ------------------------------------------------ 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ------------------------------------------------ 
 

Enquiries:

 
 Silence Therapeutics plc                              Tel: [phone] 
  Gem Hopkins, Head of IR & Corporate Communications 
  Investec Bank plc (Nominated Adviser and              Tel: +44 (0) 20 
   Broker)                                               7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                           Tel: +44 (0) 20 
  Consilium Strategic Communications                    3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDQLFLFZLZBBD

(END) Dow Jones Newswires

April 27, 2021 02:00 ET (06:00 GMT)